Jilin Jian Yisheng Pharmaceutical Co Ltd (002566) — Tangible Net Worth Ratio

Latest as of March 2026: 95.4%

Jilin Jian Yisheng Pharmaceutical Co Ltd (002566) has a Tangible Net Worth Ratio of 95.4% as of March 2026. This metric is calculated by deducting intangible assets (CN¥108.13 Million) from net assets (CN¥2.35 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore 002566 year-over-year net asset growth to track the company's year-over-year net asset growth rate.

Tangible NW Ratio

95.4%
Tangible equity / total equity

Net Assets (Equity)

CN¥2.35 Billion
CNY

Intangible Assets

CN¥108.13 Million
Goodwill, patents, brand value

Total Assets

CN¥3.01 Billion
CNY

Jilin Jian Yisheng Pharmaceutical Co Ltd Tangible Net Worth Ratio (2006–2025)

This chart shows how Jilin Jian Yisheng Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 20 annual periods from 2006 to 2025. As of March 2026, the ratio stands at 95.4%, reflecting net assets of CN¥2.35 Billion with intangible assets of CN¥108.13 Million CNY. For live market cap and overall valuation, see Jilin Jian Yisheng Pharmaceutical Co Ltd (002566) total market value.

Annual Tangible Net Worth Ratio for Jilin Jian Yisheng Pharmaceutical Co Ltd (2006–2025)

The table below presents the year-by-year Tangible Net Worth Ratio for Jilin Jian Yisheng Pharmaceutical Co Ltd from 2006 to 2025, covering 20 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore Jilin Jian Yisheng Pharmaceutical Co Ltd capital spending ratio to see what proportion of operating cash flow is directed to capital expenditures.

Year Tangible NW Ratio Net Assets (CNY) Intangible Assets Total Assets Change (pp)
2025 95.3% CN¥2.33 Billion CN¥108.66 Million CN¥2.96 Billion ▲ +0.1 pp
2024 95.2% CN¥2.33 Billion CN¥111.35 Million CN¥2.97 Billion ▲ +0.1 pp
2023 95.1% CN¥2.33 Billion CN¥114.18 Million CN¥3.05 Billion ▲ +0.3 pp
2022 94.8% CN¥2.25 Billion CN¥117.03 Million CN¥2.97 Billion ▲ +0.3 pp
2021 94.5% CN¥2.20 Billion CN¥119.96 Million CN¥2.86 Billion ▲ +0.3 pp
2020 94.2% CN¥2.13 Billion CN¥123.41 Million CN¥2.80 Billion ▼ -3.1 pp
2019 97.3% CN¥2.06 Billion CN¥54.74 Million CN¥2.50 Billion ▲ +0.2 pp
2018 97.2% CN¥1.97 Billion CN¥55.33 Million CN¥2.55 Billion ▲ +0.2 pp
2017 97.0% CN¥1.90 Billion CN¥57.29 Million CN¥2.65 Billion ▲ +0.2 pp
2016 96.8% CN¥1.80 Billion CN¥58.52 Million CN¥2.67 Billion ▲ +0.2 pp
2015 96.6% CN¥1.75 Billion CN¥60.14 Million CN¥2.63 Billion ▼ -2.5 pp
2014 99.1% CN¥1.75 Billion CN¥16.43 Million CN¥2.49 Billion ▲ +0.0 pp
2013 99.0% CN¥1.68 Billion CN¥16.48 Million CN¥1.89 Billion ▲ +0.1 pp
2012 98.9% CN¥1.59 Billion CN¥17.40 Million CN¥1.66 Billion ▼ -0.1 pp
2011 99.0% CN¥1.51 Billion CN¥15.25 Million CN¥1.58 Billion ▲ +2.3 pp
2010 96.7% CN¥359.40 Million CN¥11.77 Million CN¥515.06 Million ▲ +0.0 pp
2009 96.7% CN¥280.99 Million CN¥9.22 Million CN¥427.66 Million ▼ -0.2 pp
2008 96.9% CN¥219.89 Million CN¥6.82 Million CN¥347.32 Million ▲ +0.4 pp
2007 96.5% CN¥205.59 Million CN¥7.27 Million CN¥341.67 Million ▼ -0.7 pp
2006 97.1% CN¥238.69 Million CN¥6.83 Million CN¥338.04 Million
pp = percentage points